Verastem, Inc. current report, 18 September 2012

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Verastem, Inc. on September 18, 2012. The filing reports corporate governance changes, specifically the election of a new director and the appointment of a new Chief Executive Officer.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.

Material Changes

  • Board Expansion: The Board of Directors increased its size from 6 to 7 members.
  • New Director: S. Louise Phanstiel was elected as a director and appointed to the Audit Committee.
  • Executive Appointment: Christoph Westphal, M.D., Ph.D., was appointed as President and Chief Executive Officer.

Compensatory Arrangements and Outlook

Director Compensation (S. Louise Phanstiel):

  • Received an initial stock option grant of 25,000 shares.
  • Eligible for annual cash retainer fees and an annual stock option grant of 12,500 shares.
  • Entered into a customary indemnification agreement.
Executive Compensation (Christoph Westphal):
  • Received a stock option grant of 625,000 shares subject to time-based vesting.
  • Granted 206,612 restricted stock units (RSUs) subject to time-based vesting.
  • Granted 103,306 RSUs subject to performance-based vesting.
  • These equity awards are in lieu of cash compensation.
  • All awards vest immediately upon a change in control of the Company.
Risks and Contingencies:

Dr. Westphal agreed to standard non-solicitation, non-competition, confidential information, and invention assignment agreements. No other risks or contingencies were disclosed in this filing.

Investor Verification Checklist

  • Verify the vesting schedules and performance metrics for Dr. Westphal's restricted stock units.
  • Confirm the total number of outstanding shares and the dilution impact of the new grants (625,000 options + 309,918 RSUs for CEO; 25,000 options for Director).
  • Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the leadership changes.
  • Check subsequent filings for the Company's cash position, as the CEO's compensation is entirely equity-based, implying potential cash flow constraints.